SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The S&P 500 is trading lower as investors weigh rising Treasury yields and an industry-wide debate over the pace of artificial intelligence development. Market participants remain cautious and volatile ahead of the upcoming Federal Reserve policy decision.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending as traders react to rising long-term Treasury yields and intensifying debate over a potential Federal Reserve rate hike in September. Investors are focused on the intersection of persistent inflation pressures—exacerbated by rising oil prices—and active policy intervention, including Treasury bond buybacks, with many questioning the ability of these measures to offset the broader upward pressure on yields.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is trending following the official completion of the acquisition of Chain Technology and Services, which integrates significant payments infrastructure into the Onyx ecosystem. While some traders view this as a bullish foundation for a future neobank, others remain skeptical, dismissing the movement as a potential pump-and-dump scheme characterized by ongoing volatility and dilution concerns.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The index is fluctuating as traders react to conflicting signals regarding AI development and potential rate hikes, with market sentiment heavily influenced by uncertainty over AI-related capital expenditure and Federal Reserve policy. Despite early selling pressure, the market has seen aggressive intraday bounces, reflecting a high level of debate over the durability of the AI trade versus macroeconomic risks.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

The conversation is highly fragmented and politically charged, with participants debating the economic impact of the ongoing conflict in Iran, rising fuel prices, and recent reports regarding the financing of the Trump family wedding. Traders are also actively discussing and clashing over recent geopolitical maneuvers, AI regulatory policies, and the political implications of upcoming midterm elections.

Nasdaq, Inc. is a holding company, which engages in trading, clearing, exchange technology, regulatory, securities listing, information, and public and private company services. It operates through the following segments: Capital Access Platforms, Financial Technology, and Market Services. The Capital Access Platforms segment delivers liquidity, transparency, and integrity to the corporate issuer and investment community by empowering clients to effectively navigate the capital markets, achieve their sustainability goals, and drive governance excellence. The Financial Technology segment offers platforms that improve the liquidity, transparency, and integrity of the global economy by architecting and operating the markets. The Market Services segment includes equity derivative trading and clearing, cash equity trading, fixed income, currency, and commodities trading. The company was founded by Gordon S. Macklin in 1971 and is headquartered in New York, NY.

Nasdaq Inc - Ordinary Shares - 144A

Nasdaq Inc

Investors are actively discussing Nasdaq's recent investment in the parent company of the crypto exchange Kraken, which aims to facilitate 24/7 trading of tokenized stocks by 2027. Additionally, the conversation reflects broader market sentiment regarding potential interest rate cuts and general technical analysis trends.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending following a recent initiation of coverage by Rosenblatt, which issued a Buy rating and a bullish price target, highlighting the company's positioning as a key player in AI optical infrastructure. While some traders view the recent price decline as a significant dip-buying opportunity fueled by sector-wide volatility, others express frustration over the stock's sluggish movement and institutional pressure.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is trending as the community reacts to the company reaching a key milestone in its Phase 3 APPROACH trial ahead of schedule, with investors maintaining optimism for a Q4 topline data readout. Sentiment is further bolstered by the closing of a recent financing round and ongoing optimism regarding the broader psychedelic sector's regulatory and M&A landscape.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is trending amid high volatility as traders debate the sustainability of the AI semiconductor rally, with many dismissing concerns over AI development slowdowns as temporary "FUD" while others express caution regarding potential market corrections. The sentiment remains heavily polarized between those buying the dip for long-term growth and others positioning for further downside driven by macroeconomic pressures like rising oil prices and interest rate expectations.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending as traders focus on the upcoming HARMONi-3 clinical trial readout and a November FDA decision for ivonescimab, which is being positioned as a potential competitor to Keytruda. While sentiment remains divided over the drug's clinical data and the company's financial runway, the community is closely monitoring significant insider buying and elevated short interest as indicators of a possible short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aktis Oncology Details Two-Phase 1b Plan for AKY-2519 in Prostate Cancer and Solid Tumors

Aktis Oncology (NASDAQ:AKTS) outlined its clinical development strategy for AKY-2519, a B7-H3 targeted miniprotein radioconjugate, emphasizing a two-trial approach intended to generate...

Aktis Oncology (AKTS) Expected to Announce Earnings on Friday

Aktis Oncology (NASDAQ:AKTS) will be releasing its Q1 2026 earnings on Friday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-8-akoustis-technologies-inc-stock...

Aktis Oncology (NASDAQ:AKTS) Shares Gap Down - What's Next?

Aktis Oncology (NASDAQ:AKTS) Shares Gap Down - Time to Sell...

Aktis Oncology (NASDAQ:AKTS) Stock Price Crosses Above Fifty Day Moving Average - Time to Sell?

Aktis Oncology (NASDAQ:AKTS) Stock Crosses Above Fifty Day Moving Average - Time to Sell...

Wall Street Analysts Predict a 74.73% Upside in Aktis (AKTS): Here's  What You Should Know

The mean of analysts' price targets for Aktis (AKTS) points to a 74.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Aktis Oncology (NASDAQ:AKTS) Shares Down 3.7% - Here's Why

Aktis Oncology (NASDAQ:AKTS) Stock Price Down 3.7% - Time to Sell...

Aktis Oncology (NASDAQ:AKTS) Receives Consensus Rating of "Buy" from Analysts

Shares of Aktis Oncology (NASDAQ:AKTS - Get Free Report) have been given an average rating of "Buy" by the five analysts that are presently covering the stock, MarketBeat Ratings reports. Five...

Q1 EPS Estimates for Aktis Oncology Boosted by HC Wainwright

Aktis Oncology (NASDAQ:AKTS - Free Report) - Investment analysts at HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for Aktis Oncology in a research report issued to clients...

HC Wainwright Comments on Aktis Oncology Q1 Earnings

Aktis Oncology (NASDAQ:AKTS - Free Report) - Research analysts at HC Wainwright issued their Q1 2027 EPS estimates for shares of Aktis Oncology in a research note issued on Tuesday, March 31st. HC...

Aktis Oncology (NASDAQ:AKTS) Given New $33.00 Price Target at HC Wainwright

HC Wainwright boosted their price objective on Aktis Oncology from $30.00 to $33.00 and gave the company a "buy" rating in a report on Tuesday...

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company was founded by Todd Foley, Patrick Baeuerle and Brian Goodman in August 2020 and is headquartered in Boston, MA.

Aktis Oncology Inc

Neutral Sentiment

50bps hike

25bps hike

No change

25bps cut

The Federal Reserve's September FOMC meeting concludes Wednesday, September 16, with a rate decision due at 2:00 PM ET, following Tuesday's CPI report that showed inflation still running above the Fed's 2% target. What do you think the Fed decides at this week's FOMC meeting? Vote and explain your reasoning in the comments.

The Fed&#39;s rate decision comes Wednesday at 2PM ET. What do you think happens?

Stocktwits

The Fed's rate decision comes Wednesday at 2PM ET. What do you think happens?

Current Price	$23.17
Prev Close	$23.30
Open	$23.36
Dividend Yield	N/A
50-Day Moving Average	$24.89
Beta	2.08
Avg. Volume	273,764.34
PE Ratio	N/A

52-Week High	$34.19
52-Week Low	$14.72
Market Capitalization	$1.3B
EPS (Annual)	-$1.19
Price to Book	2.64
Revenue Per Employee	$82,240.51

Feed

News

Sentiment

Earnings

Fundamentals

Info

AKTS Fundamentals